- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Biocad Forges Ahead With Biosimilar Infliximab
Biocad, a Russia-based drug manufacturer, received approval for an infliximab biosimilar (referencing Remicade) from Russia’s Federal Drug Control Service last month. The company anticipates expanding to other markets as soon as later this year, or early 2019.
Biocad, a Russia-based drug manufacturer, received approval for an infliximab biosimilar (referencing Remicade) from Russia’s Federal Drug Control Service last month. The company anticipates expanding to other markets as soon as later this year, or early 2019.
In order to receive regulatory approval, Biocad completed international clinical studies of the infliximab biosimilar in direct comparison with the reference product. The infliximab biosimilar was investigated in treating indications of its reference, specifically ankylosing spondylitis and rheumatoid arthritis (RA).
The studies found that the therapeutic effects of the biosimilar were shown to be equivalent to the reference. In addition, the safety profiles of the 2 drugs were also similar in the long-term.
Biocad reportedly believes that India will be the first country to receive shipments of the biosimilar, where the infliximab market is valued at around $50 million for 2018.
Infliximab is the fourth monoclonal antibody biosimilar for which Biocad has gained regulatory approval. Past approvals include biosimilars of bevacizumab, trastuzumab, and rituximab. The drug maker won its patent dispute over rituximab with the reference manufacturer, Roche, last October.
Around the same time this legal win was announced, Biocad revealed intentions to enter the European market with oncological and autoimmune therapies. The company has both innovative and biosimilar products currently for sale in Europe, spanning treatments for melanoma; breast, stomach, kidney, and lung cancer; RA; psoriasis; and multiple sclerosis.
“As for the European Union countries, where the approval of biological product goes under centralized procedure through the European Medicines Agency, taking into account the need for local clinical trials, we expect to get marketing authorization for biological products in 2021,” said Dmitry Morozov, general director of Biocad.
According to a press release, the company estimates that, in 2021, its generics of oncology drugs docetaxel, paclitaxel, pemetrexed, and irinotecan will also enter the European market.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
